Health-related quality of life in outpatients with schizophrenia: factors that determine changes over time

Imagem de Miniatura
Arquivos
art_DOMENECH_Healthrelated_quality_of_life_in_outpatients_with_schizophrenia_2018.PDF (650.54 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER HEIDELBERG
Autores
DOMENECH, Cristina
ALTAMURA, Carlo
BERNASCONI, Corrado
CORRAL, Ricardo
EVANS, Jonathan
MALLA, Ashok
KREBS, Marie-Odile
NORDSTROEM, Anna-Lena
ZINK, Mathias
Citação
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, v.53, n.3, p.239-248, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The objective of this study was to analyze the clinical factors associated with changes in HRQoL in outpatients with schizophrenia using both generic and condition-specific HRQoL scales. Adult outpatients with schizophrenia at least 18 years of age who did not have an acute psychotic exacerbation in the 3 months prior to baseline were recruited. PANSS dimensions were calculated based on Lindenmayer et al.'s five factors. HRQoL data were assessed by patients using the Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5 Dimension (EQ-5D) questionnaires. Out of the 1345 patients included at baseline, 1196 (89%) were evaluated at 12 months. Regression models showed that the factor most consistently associated with HRQoL at endpoint was change in the PANSS negative symptoms score. A decrease in the PANSS negative symptoms score from baseline to 1 year was associated with a decrease in HRQoL during the same period. There were also significant associations of the change in PANSS excitatory factor with all the HRQoL scales except the SF-36 PCS. Female gender was associated with a decrease in all HRQoL ratings. There was also a relationship between years since onset and HRQoL. The longer the time since illness onset, the larger the decrease in HRQoL. This study has found that, in outpatients with schizophrenia, changes in negative and excitement symptoms may have a greater an association with HRQoL than changes in positive, cognitive and depressive symptoms.
Palavras-chave
Schizophrenia, Health-related quality of life, Symptoms, Course, Community
URI
https://observatorio.fm.usp.br/handle/OPI/26415
Referências
  1. American Psychiatric Association, 2000, DIAGN STAT MAN MENT
  2. Augustovski FA, 2008, J CLIN EPIDEMIOL, V61, P1279, DOI 10.1016/j.jclinepi.2008.05.004
  3. Awad AG, 2012, PHARMACOECONOMICS, V30, P183, DOI 10.2165/11594470-000000000-00000
  4. Awad AG, 1997, PHARMACOECONOMICS, V11, P32, DOI 10.2165/00019053-199711010-00005
  5. Bobes J, 2005, EUR PSYCHIAT, V20, pS313, DOI 10.1016/S0924-9338(05)80182-8
  6. Boyer L, 2013, EXPERT REV PHARM OUT, V13, P343, DOI [10.1586/erp.13.15, 10.1586/ERP.13.15]
  7. Brazier J, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18340
  8. Browne S, 1996, ACTA PSYCHIAT SCAND, V94, P118, DOI 10.1111/j.1600-0447.1996.tb09835.x
  9. Bystritsky A, 2001, DEPRESS ANXIETY, V14, P214, DOI 10.1002/da.1069
  10. CELLA DF, 1995, SEMIN ONCOL, V22, P73
  11. Ciconelli RM, 1999, REV BRAS REUMATOL, V39, P143, DOI 10.1590/S0482-50042010000300005
  12. Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, P567, DOI 10.1234/12345678
  13. Cordoba Rodrigo, 2012, Rev Colomb Psiquiatr, V41, P340, DOI 10.1016/S0034-7450(14)60009-3
  14. Coretti S, 2014, EXPERT REV PHARM OUT, V14, P221, DOI 10.1586/14737167.2014.894462
  15. Cramer JA, 2000, SCHIZOPHRENIA BULL, V26, P659, DOI 10.1093/oxfordjournals.schbul.a033484
  16. Devlin NJ, 2017, APPL HEALTH ECON HEA, V15, P127, DOI 10.1007/s40258-017-0310-5
  17. Dimitriou P, 2009, J PSYCHIATR MENT HLT, V16, P546, DOI 10.1111/j.1365-2850.2009.01413.x
  18. Dolan P., 1995, SOCIAL TARIFF EUROQO
  19. Fransen M, 1999, RHEUMATOLOGY, V38, P807, DOI 10.1093/rheumatology/38.9.807
  20. Galuppi A, 2010, INT J MENT HEALTH SY, V4, DOI 10.1186/1752-4458-4-31
  21. Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7
  22. Guajardo VD, 2015, J STROKE CEREBROVASC, V24, P201, DOI 10.1016/j.jstrokecerebrovasdis.2014.08.020
  23. Hermes EDA, 2012, J CLIN PSYCHIAT, V73, P526, DOI 10.4088/JCP.11m07162
  24. Hsiao CY, 2012, J CLIN NURS, V21, P2367, DOI 10.1111/j.1365-2702.2012.04067.x
  25. Janssen MF, 2013, QUAL LIFE RES, V22, P1717, DOI 10.1007/s11136-012-0322-4
  26. JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843
  27. JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437
  28. Jenkinson C, 1999, J PUBLIC HEALTH MED, V21, P372, DOI 10.1093/pubmed/21.4.372
  29. Katschnig H, 2000, ACTA PSYCHIAT SCAND, V102, P33, DOI 10.1034/j.1600-0447.2000.00006.x
  30. KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261
  31. Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8
  32. Linde L, 2008, J RHEUMATOL, V35, P1528
  33. LINDENMAYER JP, 1995, SCHIZOPHR RES, V14, P229, DOI 10.1016/0920-9964(94)00041-6
  34. Haro JM, 2015, SCHIZOPHR RES, V169, P234, DOI 10.1016/j.schres.2015.09.001
  35. McCrone P, 2009, J MENT HEALTH POLICY, V12, P27
  36. Mulhern B, 2014, BRIT J PSYCHIAT, V205, P236, DOI 10.1192/bjp.bp.112.122283
  37. Narvaez JM, 2008, SCHIZOPHR RES, V98, P201, DOI 10.1016/j.schres.2007.09.001
  38. Ojeda N, 2012, ACTAS ESP PSIQUIATRI, V40, P10
  39. Papaioannou D, 2011, VALUE HEALTH, V14, P907, DOI 10.1016/j.jval.2011.04.006
  40. Payakachat N, 2015, PHARMACOECONOMICS, V33, P1137, DOI 10.1007/s40273-015-0295-6
  41. Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
  42. Rofail D, 2016, QUAL LIFE RES, V25, P201, DOI 10.1007/s11136-015-1057-9
  43. Rouillon F, 2013, ACTA NEUROPSYCHIATR, V25, P297, DOI 10.1017/neu.2013.7
  44. Ruggeri M, 2005, BRIT J PSYCHIAT, V187, P121, DOI 10.1192/bjp.187.2.121
  45. Schram MT, 2009, CURR DIABETES REV, V5, P112, DOI 10.2174/157339909788166828
  46. Sonntag M, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0315-4
  47. Stefanovics EA, 2014, PSYCHIAT RES, V219, P283, DOI 10.1016/j.psychres.2014.04.041
  48. Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1167, DOI 10.1016/S0895-4356(98)00108-5
  49. WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
  50. Wilkinson G, 2000, BRIT J PSYCHIAT, V177, P42, DOI 10.1192/bjp.177.1.42
  51. Xiang YT, 2010, AUST NZ J PSYCHIAT, V44, P450, DOI 10.3109/00048670903489858
  52. Zeng YC, 2015, PSYCHIAT RES, V228, P724, DOI 10.1016/j.psychres.2015.05.033

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS